Abbott LaboratoriesvsVera Therapeutics

ABT and VERA stock compared: price, dividend, valuation and results, from SEC filings.

ABT

Abbott Laboratories

$103.00

Value $179B

-0.84%
ABT's page

VERA

Vera Therapeutics, Inc.

$25.45

Value $1.8B

-4.86%
VERA's page

Abbott Laboratories (ABT) has a market value of $179B and Vera Therapeutics (VERA) $1.8B. Over the last year, with dividends, ABT moved -16.3% and VERA -10.9%. Dividend yield: ABT 2.45%, VERA none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABT$179B

    VERA$1.8B

    ABT is 97 times VERA

  • Revenue, 12 months

    ABT$48.2B

    VERA–

  • Net income, 12 months

    ABT$4.7B

    VERA-$415M

  • Operating margin

    ABT13.8%

    VERA–

  • ROIC

    ABT6.3%

    VERA-36.7%

    43.0 points apart

  • P/E

    ABT38.1

    VERA–

  • Dividend yield

    ABT2.5%

    VERA0.0%

    2.5 points apart

  • 5-year return

    ABT-10.3%

    VERA-18.4%

    8.1 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABT-10.3%

VERA-18.4%

5010015020222023202420252026
Returns by period
PeriodABTWith dividendsVERAWith dividends
1 year since November 19, 2025-16.3%Price -18.4%-10.9%Price -10.9%
3 years since November 20, 2023+8.4%+2.7% a yearPrice +1.8%+88.5%+23.5% a yearPrice +88.5%
5 years since November 19, 2021-10.3%-2.1% a yearPrice -18.8%-18.4%-4.0% a yearPrice -18.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABTAbbott LaboratoriesVERAVera Therapeutics

Valuation

ABTVERA
Valuation
Price$103.00$25.45
Market value$179B$1.8B
Enterprise value (EV)$206B$1.5B
P/E38.1–
P/E, 5-year median33.7–
P/B3.55.5
EV/EBIT31.0–
Free cash flow yield3.8%–

Results and growth

ABTVERA
Results and growth
Revenue, 12 months$48.2B–
Net income, 12 months$4.7B-$415M
Free cash flow, 12 months$6.8B-$376M
Earnings per share, 12 months$2.69-$5.90
Revenue growth, year on year5.7%–
Revenue growth a year, past+5.1%over 5 years–
EPS growth a year, past+8.3%over 5 years–

Margins and returns on capital

ABTVERA
Margins and returns on capital
Gross margin56.9%–
Operating margin13.8%–
Net margin9.8%–
ROIC6.3%-36.7%
ROE9.1%-92.5%

Balance sheet

ABTVERA
Balance sheet
Cash$4.3B$384M
Total debt$31.2B$75M
Net debt / EBITDA3.3–
Interest cover6.7×-42.4×

Dividends and buybacks

ABTVERA
Dividends and buybacks
Dividend yield2.5%–
Dividend per share, 12 months$2.52–
Dividend growth a year, past+10.4%over 5 years–
Buyback yield0.5%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABT or VERA

Didn't find what you were looking for?

Ask us
Which is bigger, Abbott Laboratories or Vera Therapeutics?

By market value, Abbott Laboratories ($179B) is about 97.3 times Vera Therapeutics ($1.8B), at today's prices.

How did ABT and VERA stock do over the last 5 years?

Since November 19, 2021, ABT's price moved -18.8% and VERA's -18.4%. With dividends: ABT -10.3% (-2.1% a year), VERA -18.4% (-4.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABT or VERA?

The dividend yield at today's price is 2.45% for Abbott Laboratories and none for Vera Therapeutics. Over the last twelve months they paid $2.52 and – per share.

Which is the better investment, Abbott Laboratories or Vera Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.